Cardizem (Diltiazem): Clinical Guide
Indications
Cardizem is FDA-approved for hypertension, chronic stable angina, and angina due to coronary artery spasm (oral formulation), while IV diltiazem is the preferred agent for acute rate control in supraventricular tachycardia, particularly atrial fibrillation with rapid ventricular response. 1
Specific Clinical Uses:
- Acute SVT/Atrial Fibrillation with RVR: IV diltiazem achieves rate control within 5 minutes, significantly faster than digoxin (which takes 3 hours), making it superior for emergency rate control 2
- Chronic conditions: Hypertension and stable angina (oral formulations) 1
- Unstable angina: Continuous IV infusion effectively controls symptoms in 94% of patients 3
Dosing
IV Administration for Acute SVT/Atrial Fibrillation
Initial bolus: 0.25 mg/kg IV over 2 minutes 4
However, lower doses (≤0.2 mg/kg) are equally effective and significantly safer, reducing hypotension risk by 61% (adjusted OR 0.39) without compromising rate control efficacy (70.5% vs 77.1% success rate) 5. This is particularly important in real-world practice where hypotension rates increase from 18% with low-dose to 35-42% with standard/high doses 5.
Maintenance infusion: 5-10 mg/hour, up to 15 mg/hour 4
If initial bolus ineffective: May repeat with 0.35 mg/kg after 15 minutes 4
Oral Dosing
Hypertension:
- Start: 180-240 mg once daily (extended-release)
- Range: 240-360 mg daily
- Maximum studied: 480 mg daily 1
Angina:
- Start: 120-180 mg once daily
- Maximum: 480 mg daily
- Titrate over 7-14 days 1
Special Populations
Obese patients: Use ideal body weight for dosing calculations rather than actual body weight, as this better aligns with guideline targets and avoids underdosing 6. Actual body weight dosing in obese patients results in significantly lower mg/kg doses (0.16 vs 0.21 mg/kg) 6.
Contraindications (Absolute)
Do not use diltiazem in the following conditions 1:
- Sick sinus syndrome (unless functioning pacemaker present)
- Second- or third-degree AV block (unless functioning pacemaker present)
- Hypotension (systolic BP <90 mmHg)
- Acute MI with pulmonary congestion on chest x-ray
- WPW syndrome with atrial fibrillation/flutter 4
- Decompensated systolic heart failure/LV dysfunction 4
- Cardiogenic shock 4
Precautions and Warnings
Heart Failure Considerations
Critical caveat: While diltiazem is contraindicated in decompensated heart failure, recent data shows it can be used cautiously in stable patients with reduced ejection fraction (EF <50%). Among patients with EF <50% who received IV diltiazem, 30% were safely discharged home 7. However, worsening heart failure occurred in 17% of admitted patients with reduced EF versus 4.8% with preserved EF (p=0.005) 7.
Acute kidney injury risk: Patients with low EF have significantly higher rates of AKI within 48 hours (10% vs 3.6%, p=0.002), though no increased risk of hypotension, ICU transfer, or mortality 8.
Practical approach: In patients with EF <50% and AF with RVR, diltiazem can be used if the patient is hemodynamically stable and not in acute decompensation, but monitor closely for worsening heart failure and renal function 7, 8.
Drug Interactions
Diltiazem is a CYP3A4 substrate and moderate inhibitor 4. Key interactions include:
- Avoid with dofetilide (contraindicated)
- Increases levels of: simvastatin, cyclosporine, digoxin, beta-blockers
- Grapefruit juice increases diltiazem levels
Adverse Effects
Most common and dose-dependent 4, 1:
- Hypotension (18-42% depending on dose)
- First-degree AV block
- Sinus bradycardia
- Dizziness
- Worsening heart failure in patients with pre-existing ventricular dysfunction
- Abnormal liver function tests (rare: acute hepatic injury)
Monitoring Recommendations
Acute IV Administration:
- Continuous cardiac monitoring during bolus and initial infusion
- Blood pressure: Check at 0,5,10,15,30,60,120, and 180 minutes 2
- Heart rate: Same intervals as BP
- ECG monitoring: Watch for AV block, bradycardia
Chronic Oral Therapy:
- Blood pressure: Monitor every 2 weeks during titration (maximum effect at 14 days) 1
- Heart rate: Assess for excessive bradycardia
- Liver function tests: Baseline and periodically
- Renal function: Especially in patients with heart failure or baseline renal dysfunction
High-Risk Patients (EF <50%):
- Monitor for signs of worsening heart failure within 24-48 hours 7
- Renal function: Check within 48 hours (higher AKI risk) 8
- Consider admission rather than discharge if any concern for decompensation
Clinical Pearls
Rate control efficacy: Diltiazem achieves therapeutic response (HR <100) in 65-69% at 30 minutes, 86-87% at 3 hours, and >93% at 6 hours 6.
Dosing strategy: Start with lower doses (≤0.2 mg/kg) to minimize hypotension risk while maintaining efficacy 5. Higher initial doses increase odds of early rate control but also increase adverse events 6.
Combination therapy: Can be safely combined with nitrates and antihypertensives, though doses may need adjustment 1. No advantage to combining with digoxin in acute settings within 3 hours 2.